John joined the Kiniksa team in 2016 with over 25 years of experience spanning from basic biological/medical science through all phases of clinical development and regulatory strategy for small molecules and biologics. He was most recently clinical research head of the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Inc., where he was responsible for bringing forward programs in diabetes, heart failure, lipids, and metabolic liver disease from preclinical through early clinical development and proof of concept. John previously served as Chief Medical Officer of Cerenis Therapeutics in France, a publicly traded company on the Euronext exchange. He was responsible for designing and executing clinical trials and regulatory strategy for a portfolio of products relating to HDL and reverse lipid transport and also played an instrumental role in the company’s capital-raising efforts, including its initial public offering. Before moving to France, John was Global Clinical Leader at Bayer HealthCare Pharma, where he was responsible for the Phase III program, NDA filing, and launch of Xarelto® in atrial fibrillation as well as Xarelto Life Cycle Management. He started in the pharmaceutical industry at Merck & Co., Inc., in cardiovascular clinical research and clinical pharmacology, leading programs in thrombosis and dyslipidemia that spanned the early- and late-stage portfolio, including Zocor® and Aggrastat®, the Vytorin®, Zetia®, and Tredaptive® clinical development programs and NDAs, as well as in-licensing activities in cardiovascular disease. John obtained an MD, PhD from Duke University, where his PhD work focused on the protein chemistry of immune mediators. He subsequently completed a residency in internal medicine and a fellowship in cardiovascular medicine at the Brigham and Women’s Hospital, including a postdoctoral fellowship at the Massachusetts Institute of Technology researching the role of inflammatory mediators in vascular disease and restenosis. He received Board certification in internal medicine and cardiology and is a Fellow of the American College of Cardiology. He was a member of the clinical faculty at the University of Pennsylvania as a clinical associate and served as an attending physician for 10 years, precepting cardiology fellows in the HUP outpatient cardiology clinic. John has authored more than 75 peer-reviewed journal articles and abstracts. He received a bachelor of arts, summa cum laude, and a bachelor of science, summa cum laude, from Tulane University.
What is John F. Paolini's net worth?
The estimated net worth of John F. Paolini is at least $1.18 million as of September 3rd, 2024. Dr. Paolini owns 52,038 shares of Kiniksa Pharmaceuticals stock worth more than $1,176,579 as of March 14th. This net worth estimate does not reflect any other investments that Dr. Paolini may own. Additionally, Dr. Paolini receives an annual salary of $855,790.00 as Executive Vice President, Chief Medical Officer at Kiniksa Pharmaceuticals. Learn More about John F. Paolini's net worth.
How old is John F. Paolini?
What is John F. Paolini's salary?
As the Executive Vice President, Chief Medical Officer of Kiniksa Pharmaceuticals, Ltd., Dr. Paolini earns $855,790.00 per year. The highest earning executive at Kiniksa Pharmaceuticals is Mr. Sanj K. Patel, CEO & Chairman of the Board, who commands a salary of $1,570,000.00 per year. Learn More on John F. Paolini's salary.
How do I contact John F. Paolini?
The corporate mailing address for Dr. Paolini and other Kiniksa Pharmaceuticals executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals can also be reached via phone at (781) 431-9100 and via email at ir@kiniksa.com. Learn More on John F. Paolini's contact information.
Has John F. Paolini been buying or selling shares of Kiniksa Pharmaceuticals?
John F. Paolini has not been actively trading shares of Kiniksa Pharmaceuticals during the past quarter. Most recently, John F. Paolini sold 60,692 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a transaction totalling $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares of the company's stock, valued at $1,359,232.56. Learn More on John F. Paolini's trading history.
Who are Kiniksa Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Kiniksa Pharmaceuticals?
In the last year, insiders at the sold shares 13 times. They sold a total of 378,579 shares worth more than $9,380,104.31. The most recent insider tranaction occured on March, 12th when CAO Michael R Megna sold 9,051 shares worth more than $203,194.95. Insiders at Kiniksa Pharmaceuticals own 54.6% of the company.
Learn More about insider trades at Kiniksa Pharmaceuticals. Information on this page was last updated on 3/12/2025.